Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. lessened its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 3.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 123,705 shares of the company’s stock after selling 3,789 shares during the period. Corebridge Financial Inc.’s holdings in Recursion Pharmaceuticals were worth $836,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock valued at $229,908,000 after purchasing an additional 9,737,196 shares during the last quarter. State Street Corp increased its stake in Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares in the last quarter. FMR LLC raised its holdings in shares of Recursion Pharmaceuticals by 2.1% in the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after buying an additional 170,810 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 13.7% during the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after buying an additional 656,003 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Recursion Pharmaceuticals by 17.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company’s stock valued at $15,372,000 after buying an additional 333,323 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on RXRX. Leerink Partners lowered their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.25.

Recursion Pharmaceuticals Stock Down 11.9 %

Shares of RXRX opened at $4.24 on Friday. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -2.77 and a beta of 1.00. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.06 and a 52 week high of $12.36. The stock’s 50-day moving average price is $7.22 and its 200-day moving average price is $6.95. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. During the same quarter in the prior year, the business posted ($0.42) earnings per share. The firm’s revenue was down 57.8% compared to the same quarter last year. On average, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.